Life Sciences Glossary: 80+ Biotech and Biopharma Terminology Explained

Why Terminology Matters in Life Sciences

The gap between a great idea and a funded, clinical-stage company often comes down to communication. Founders who can speak fluently about IND applications, pharmacokinetics, and Series A dynamics are taken more seriously by investors. Investors who understand BLA submissions and orphan drug designations ask better questions. Students who arrive knowing the difference between a Phase I and a Phase III trial hit the ground running.

Our observation: In California Life Sciences’ FAST Program, companies that enter with a strong command of regulatory and funding terminology move through the program faster. Not because they have better science, but because they can translate that science into terms investors and partners understand.

California’s advantage in life sciences is compounded by density. The Bay Area, San Diego, and Los Angeles biotech corridors create an environment where this vocabulary is spoken daily in pitch rooms, lab meetings, and boardrooms. Fluency matters.

Explore California Life Sciences’ FAST Program

California Life Sciences by the Numbers

California’s life sciences industry is a global anchor that directly employs hundreds of thousands of workers and supports over 750,000 jobs. California hosts more than 3,600 life sciences companies spanning pharmaceuticals, medical devices, diagnostics, and digital health, which makes this state among the most concentrated life sciences ecosystem on the planet.

Three factors reinforce each other continuously — world-class research universities (UCSF, Stanford, UCLA, UC San Diego), a deep venture capital infrastructure, and a dense talent pool. This flywheel has been spinning since Genentech launched some 50 years ago in South San Francisco in 1976.

The Drug Development Journey

Before diving into the glossary, it helps to understand the arc that most life sciences companies follow. The journey from lab discovery to approved product is long, expensive, and uncertain.

According to the BIO Clinical Development Success Rates report, only about 12% of drugs that enter Phase I trials ultimately receive FDA approval. Phase II is the most challenging transition — where most candidates fail due to insufficient efficacy rather than safety concerns. Understanding these odds is essential for founders, investors, and anyone building or evaluating a life sciences pipeline.

The Full Life Sciences Glossary

A

★ Accelerator
A structured program — typically 3–6 months — that provides early-stage life sciences companies with mentorship, resources, and access to investors in exchange for equity or a fee. Accelerators compress years of learning into weeks and often culminate in a pitch event or demo day. See also: Incubator, FAST Program.

Acquired Immunodeficiency Syndrome (AIDS)
A chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV). Biotech advances in antiretroviral therapy transformed AIDS from a fatal diagnosis into a manageable chronic condition — one of life sciences’ landmark achievements in the past half-century.

Adverse Event (AE)
Any undesirable experience associated with the use of a medical product. In clinical trials, adverse events are tracked, categorized by severity, and reported to regulators. Serious adverse events (SAEs) can pause or terminate a trial.

Advisory Board
A group of scientific, clinical, and business experts who provide strategic guidance to a life sciences company without holding formal board positions or fiduciary responsibility. A strong advisory board signals credibility to investors and can open doors that founders alone cannot.

★ Angel Investor
An individual who provides early-stage funding to startups, typically in exchange for convertible debt or equity. In life sciences, angel investors frequently have scientific or medical backgrounds and invest at the pre-seed or seed stage before institutional venture capital enters. See also: Venture Capital, Pre-Seed Funding.

Antibody
A protein produced by the immune system to identify and neutralize foreign objects such as bacteria and viruses. Monoclonal antibodies — lab-engineered versions targeting specific molecules — are among the most commercially successful drug classes in modern biotechnology, generating over $200B in global annual sales.

Assay
A test or measurement used in a laboratory to assess the presence, amount, or functional activity of a target substance. Assays are foundational tools in drug discovery, diagnostics, and quality control, and are often among the first IP assets a biotech company develops.

B

Bioavailability
The proportion of a drug that enters the bloodstream and reaches the site of action when introduced into the body. High bioavailability is a key design goal in drug formulation — especially for oral therapeutics, where the gut and liver can significantly reduce how much active drug reaches the target.

★ Bioinformatics
The application of computational tools and data analysis to biological data — particularly genomic, proteomic, and clinical datasets. Bioinformatics is central to precision medicine, drug target identification, and clinical trial design. California’s university systems and tech sector make it the global capital for bioinformatics talent.

★ Biologic (Biologic Drug)
A drug derived from biological sources — such as living cells, proteins, or nucleic acids — rather than synthesized chemically. Biologics include monoclonal antibodies, gene therapies, and vaccines. They’re often more complex and expensive to manufacture than small-molecule drugs, but can target diseases that chemical drugs cannot. See also: Small Molecule Drug, Biosimilar.

Biomanufacturing
The production of biologics and other products using living systems such as bacteria, yeast, or mammalian cell cultures. Advances in biomanufacturing automation are lowering production costs and enabling scale-up of cell and gene therapies — which historically required bespoke, expensive manufacturing for each patient.

★ Biopharma / Biopharmaceutical
A company or sector that develops pharmaceutical products derived from biological sources or using biotechnology methods. The line between traditional pharma and biopharma has blurred significantly; most major pharmaceutical companies now have large biopharma portfolios. See also: Biotech, Small Molecule Drug.

Biosimilar
A biologic drug that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Biosimilars are the biologic equivalent of generic drugs and play a significant role in reducing healthcare costs. See also: Biologic.

★ Biotechnology (Biotech)
The use of biological systems, living organisms, or their derivatives to develop products, processes, and technologies. Modern biotech spans healthcare, agriculture, industrial processes, and environmental science. See also: Life Sciences.

Bridge Financing
Short-term funding that “bridges” a company between two larger financing rounds or to a specific milestone — such as a clinical trial data readout. Bridge rounds often take the form of convertible notes and are common when a company is close to a value-creating event but needs runway to reach it. See also: Convertible Note, Series A/B/C.

BLA (Biologics License Application)
The FDA application used to request approval for a biologic product, analogous to an NDA for small-molecule drugs. Approved biologics are licensed, not simply approved, reflecting the complexity of their biological origin. See also: NDA, FDA.

C

★ CAR-T Cell Therapy
Chimeric antigen receptor T-cell therapy — a form of immunotherapy in which a patient’s own T cells are extracted, genetically engineered to target cancer cells, and reinfused. CAR-T therapies represent some of the most transformative — and expensive — treatments in oncology, with approved therapies priced between $400,000 and over $1 million per patient.

Cell Therapy
A treatment in which living cells are introduced into a patient to prevent or treat disease. Cell therapies include CAR-T, stem cell transplants, and NK cell therapies, and are a rapidly expanding frontier in regenerative medicine. The global cell therapy market is projected to exceed $30B by 2030. See also: CAR-T Cell Therapy, Gene Therapy.

Clinical-Stage Company
A life sciences company that has advanced at least one product candidate into human clinical trials. Reaching clinical stage is a major milestone — it typically unlocks larger financing rounds, partnership discussions, and signals to the market that the science has passed initial validation hurdles.

★ Clinical Trial
A research study in human volunteers designed to evaluate the safety, efficacy, and dosing of a medical intervention. Trials are structured in phases (I, II, III) and are required by regulators before any drug or device can be approved for commercial use. See also: Phase I, Phase II, Phase III, IND.

CMO (Contract Manufacturing Organization)
A company that provides outsourced pharmaceutical or biologic manufacturing services. Life sciences startups — especially pre-commercial companies — rely on CMOs to produce clinical-stage drug supplies without building their own manufacturing infrastructure. Choosing the right CMO is a critical operational decision.

Commercialization
The process of bringing a product from development to market — covering manufacturing, sales strategy, pricing, distribution, and market access. Commercialization readiness is a key focus area of CLS programs like FAST because many founders with strong science have limited experience on the business side.

Compassionate Use
A regulatory pathway that allows patients with serious or life-threatening conditions to access unapproved drugs outside of a clinical trial. Also known as “expanded access,” it provides a route for patients who have exhausted other options and can’t wait for a trial or approval. See also: FDA, IND.

Convertible Note
A short-term debt instrument that converts into equity — typically at the next financing round — rather than being repaid in cash. Convertible notes are frequently used in early-stage and bridge financing because they let investors fund a company before a formal valuation is set. See also: Bridge Financing, Pre-Seed Funding.

CRO (Contract Research Organization)
A company that provides outsourced research and clinical services — including trial management, data analysis, and regulatory submissions — to pharmaceutical and biotech companies. CROs allow smaller companies to run complex clinical programs without the overhead of large internal research teams.

★ CRISPR-Cas9
A gene-editing technology that acts as molecular scissors, allowing scientists to precisely cut and modify DNA sequences at targeted locations. CRISPR has transformed both basic research and therapeutic development — with the first CRISPR-based therapies receiving FDA approval in 2023 for sickle cell disease and beta-thalassemia. See also: Gene Editing, Gene Therapy.

D

De Novo Pathway
An FDA regulatory pathway for novel, low-to-moderate risk medical devices that aren’t substantially equivalent to any predicate device. It offers a more tailored route to clearance than the 510(k) process and is increasingly used for AI-based diagnostic tools. See also: 510(k), PMA.

★ Diagnostics
Products and technologies used to detect, identify, or characterize diseases, conditions, or pathogens. Diagnostics include laboratory tests, imaging systems, point-of-care devices, and companion diagnostics that guide treatment decisions. The global diagnostics market exceeded $100B in 2024.

Digital Health
The use of digital technologies — including mobile apps, wearables, telehealth platforms, and AI — to improve health outcomes and care delivery. Digital health is one of the fastest-growing segments of California’s life sciences ecosystem, blending the state’s tech and biotech strengths uniquely.

★ Drug Discovery
The process of identifying potential drug candidates through target identification, compound screening, and preclinical testing. Drug discovery is the first stage of a drug development program and typically precedes the formal IND application and clinical trial process. See also: Preclinical Research, Target, IND.

Due Diligence
The investigation and analysis a potential investor, acquirer, or partner conducts before finalizing a transaction. In life sciences, due diligence covers scientific validity, IP landscape, regulatory strategy, clinical data quality, team credentials, and market opportunity. Being diligence-ready is a critical milestone for any company seeking institutional funding.

E

EMA (European Medicines Agency)
The regulatory agency responsible for evaluating and approving medicines for use across the European Union. Companies with global ambitions must plan for both FDA and EMA regulatory strategies. Requirements differ, and EMA submissions are often filed in parallel with FDA applications. See also: FDA.

★ Equity Financing
Raising capital by selling shares of a company rather than taking on debt. Most life sciences startups fund operations through successive equity rounds from angel investors, then venture capital, and ultimately public markets. Each round typically dilutes existing shareholders in exchange for growth capital. See also: Series A/B/C, IPO.

Exit
The event through which investors realize a return on their investment — typically via an IPO (initial public offering) or acquisition by a larger company. Exit planning is a key strategic consideration from the earliest stages of life sciences company building because it shapes decisions around IP, partnerships, and clinical development strategy.

F

★ FAST Program
California Life Sciences’ flagship 12-week advisory program for early-stage life sciences companies. FAST provides mentorship, strategic guidance, and access to a network of over 500 investors, executives, and experts. Specialized tracks include MedTech Color (for founders of color) and Women in Bio. Since 2013, FAST alumni have raised over $2 billion in capital.

★ FDA (Food and Drug Administration)
The U.S. federal agency responsible for protecting public health by regulating drugs, biologics, medical devices, food, and cosmetics. FDA approval is the primary gateway to the U.S. market for life sciences products. The FDA approved 55 novel drugs in 2023 — one of the highest annual totals on record. See also: NDA, BLA, IND.

510(k)
An FDA premarket notification pathway for medical devices that demonstrates substantial equivalence to a legally marketed predicate device. It’s faster and less burdensome than the PMA pathway and is the most common route to market for medical devices in the US. See also: PMA, De Novo.

First-in-Human (FIH) Study
The initial Phase I clinical trial in which an investigational drug or biologic is administered to human subjects for the first time. FIH studies focus primarily on safety and pharmacokinetics — what the drug does to the body and what the body does to the drug. See also: Phase I, IND.

Formulation
The process of combining a drug substance with excipients (inactive ingredients) to create a final dosage form — such as a tablet, injection, or inhaler. Formulation significantly affects bioavailability, patient compliance, and shelf life, and is a critical component of the manufacturing development program.

★ Founder
The individual(s) who establish a life sciences company, often translating academic or industry research into a commercial venture. In California’s ecosystem, founders frequently emerge from university labs at UCSF, Stanford, UCLA, and UC San Diego — institutions that collectively generate some of the world’s most influential biomedical research.

G

★ Gene Editing
Technologies that allow targeted modifications to an organism’s DNA sequence. CRISPR-Cas9 is the most widely used platform, but others include TALEN, zinc finger nucleases, base editing, and prime editing — each offering different tradeoffs in precision, efficiency, and delivery. See also: CRISPR-Cas9, Gene Therapy.

★ Gene Therapy
A medical approach that treats or prevents disease by correcting, replacing, or silencing faulty genes. Gene therapies typically use viral vectors (such as adeno-associated viruses, or AAVs) to deliver therapeutic genetic material into target cells. Several gene therapies have received FDA approval, primarily for rare diseases. See also: Vector, CRISPR-Cas9.

★ Genomics
The study of an organism’s complete set of DNA — including all of its genes and their interactions. Genomics underpins precision medicine, drug target discovery, population health research, and companion diagnostic development. The cost of sequencing a human genome has dropped from ~$100M in 2001 to under $1,000 today.

Go-to-Market (GTM) Strategy
A plan for how a company will bring its product to customers — covering target segments, distribution channels, pricing model, reimbursement strategy, and sales approach. A clear GTM strategy is increasingly expected of life sciences companies even in early clinical stages, as investors want to see that founders understand the path to patients and revenue.

H

Health Economics and Outcomes Research (HEOR)
Research that evaluates the clinical, economic, and humanistic value of healthcare interventions. HEOR evidence is used to support payer and formulary decisions — and is increasingly required by health systems and insurers alongside traditional clinical trial data, particularly for high-cost therapies like cell and gene treatments.

Human Genome Project
A landmark international scientific effort (1990–2003) that mapped the complete human genetic sequence. It catalyzed the modern era of genomics, bioinformatics, and personalized medicine, and helped establish many of California’s foundational biotech companies. The HGP is widely considered the most consequential scientific initiative of the late 20th century.

I

★ IND (Investigational New Drug)
An application submitted to the FDA before beginning clinical trials of a new drug in humans. IND approval allows a company to ship investigational drugs across state lines and initiate trial activities. The IND package includes preclinical safety data, a proposed clinical protocol, and manufacturing information. See also: FDA, Phase I, NDA.

Incubator
A facility or program that provides early-stage companies with physical lab space, shared equipment, and sometimes mentorship or seed funding. Life sciences incubators — concentrated in the Bay Area, San Diego, and Los Angeles — dramatically lower the cost of starting a biotech company by providing shared infrastructure. See also: Accelerator.

Indication
The specific disease, condition, or patient population for which a drug or device is approved or intended. Companies often pursue multiple indications for a single asset — a strategy that can significantly expand market opportunity without developing an entirely new drug. Each indication typically requires its own clinical program.

★ Intellectual Property (IP)
Legal rights protecting inventions, discoveries, and creative works. In life sciences, IP typically refers to patents covering drug compounds, manufacturing processes, formulations, and diagnostic methods. A strong IP portfolio is a core driver of company valuation and is often the most valuable asset in a licensing deal or acquisition. See also: Patent, Licensing.

★ IPO (Initial Public Offering)
The first sale of a company’s stock to the public through a stock exchange. IPOs are a primary exit route for life sciences investors and provide companies with capital for late-stage trials, commercial launch, and operations. The biotech IPO market is highly cyclical — windows open and close based on investor sentiment and interest rates.

IVD (In Vitro Diagnostic)
A medical device used to perform diagnostic tests on biological samples — such as blood, urine, or tissue — outside the body. IVDs range from hospital lab analyzers to home pregnancy tests to molecular PCR diagnostics. They’re regulated by the FDA and subject to 510(k) or PMA pathways depending on risk classification.

L

Lead Compound
A chemical compound identified as a promising starting point for drug development based on its biological activity and safety profile. Lead optimization — improving the compound’s potency, selectivity, stability, and pharmacokinetics — is the central focus of medicinal chemistry during early-stage drug discovery.

★ Life Sciences
An umbrella term for scientific disciplines that study living organisms and their interactions with each other and their environment. In an industry context, life sciences typically refers to companies in pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health. California’s life sciences sector is the largest and most diverse in the world. See also: Biotechnology.

Licensing
An agreement by which one party (the licensor) grants another (the licensee) the right to use intellectual property in exchange for fees, milestone payments, or royalties. Licensing is one of the most common business development strategies in pharma — allowing companies to access external drug assets or monetize their own IP without building full commercial operations. See also: Royalty, Milestone Payment.

M

Market Authorization
Formal regulatory approval to sell a medical product in a specific geography. In the US, this is granted by the FDA via an NDA, BLA, or device clearance/approval; in Europe, by the EMA via a Marketing Authorisation Application (MAA). Securing market authorization is the culmination of years of development and regulatory work.

★ MedTech
An abbreviation for medical technology — the sector encompassing medical devices, diagnostic equipment, imaging systems, digital health tools, and health IT. California is a global hub for medtech innovation, home to companies developing everything from AI-powered imaging software to next-generation surgical robotics.

Milestone Payment
A payment made from one company to another upon achievement of a predefined development goal — such as completing a Phase II trial, receiving regulatory approval, or reaching a commercial sales threshold. Milestone structures are a standard component of licensing and co-development partnerships in life sciences.

★ mRNA (Messenger RNA)
A molecule that carries genetic instructions from DNA to the protein-making machinery of cells. mRNA therapeutics — popularized by COVID-19 vaccines developed by Moderna and BioNTech — represent one of the fastest-growing platforms in modern biotech. mRNA-based cancer vaccines and rare disease treatments are now in clinical development globally.

Multi-omics
The integration of data from multiple “omic” disciplines — including genomics, proteomics, metabolomics, and transcriptomics — to build a comprehensive picture of biological systems. Multi-omics approaches are accelerating drug target discovery and enabling more precise patient stratification in clinical trials.

N

★ NDA (New Drug Application)
A formal submission to the FDA requesting approval to market a new small-molecule drug in the United States. The NDA includes all preclinical data, clinical trial results, manufacturing information, and proposed labeling from the drug’s development program. See also: BLA, FDA, IND.

O

★ Oncology
The branch of medicine concerned with the study and treatment of cancer. Oncology is the largest therapeutic area in biopharma by R&D investment and consistently accounts for the largest share of new FDA drug approvals each year. California-based companies have pioneered many of the most transformative oncology treatments of the past two decades.

Orphan Drug
A drug developed to treat a rare disease affecting fewer than 200,000 people in the US. The FDA’s Orphan Drug Designation offers incentives including tax credits, fee waivers, and seven years of market exclusivity. Despite individual rarity, there are approximately 7,000 rare diseases affecting 300 million people globally — making orphan drug development a strategically and commercially attractive area.

Outcomes
Measurable results of a medical intervention, spanning clinical outcomes (patient health), humanistic outcomes (quality of life), and economic outcomes (cost-effectiveness). Demonstrating meaningful outcomes is central to market access and reimbursement strategy, particularly as payers increasingly require real-world evidence alongside clinical trial data.

P

★ Patent
A legal right granted by a government giving the inventor exclusive control over the manufacture, use, and sale of an invention for a set period — typically 20 years from filing. In life sciences, patents protect drug compounds, manufacturing processes, formulations, and medical device designs. Patent expiry opens the door to generic or biosimilar competition. See also: IP, Licensing.

Pharmacokinetics (PK)
The study of how the body absorbs, distributes, metabolizes, and excretes a drug — often summarized as ADME. PK data helps determine optimal dosing, dosing frequency, and route of administration. See also: Pharmacodynamics.

Pharmacodynamics (PD)
The study of how a drug affects the body — specifically its mechanism of action and the relationship between drug concentration and effect. PD data complements PK data in defining a drug’s therapeutic window: the range of doses that produce a therapeutic effect without causing unacceptable toxicity.

★ Phase I Clinical Trial
The first stage of human testing, focused primarily on safety, tolerability, and pharmacokinetics in a small group of participants — typically 20–100 healthy volunteers or patients. Phase I establishes the maximum tolerated dose and generates early pharmacokinetic data. Approximately 52% of drugs that enter Phase I advance to Phase II. See also: Phase II, IND.

★ Phase II Clinical Trial
A trial designed to assess preliminary efficacy and further evaluate safety in a larger patient population — typically 100–300 participants. Phase II is the most challenging transition in drug development; only about 28% of drugs that enter Phase II advance to Phase III. See also: Phase I, Phase III.

★ Phase III Clinical Trial
A large, often randomized and controlled trial — typically 1,000 or more participants — designed to confirm efficacy and systematically monitor adverse reactions at scale. Positive Phase III results are the primary basis for an NDA or BLA submission to the FDA. About 58% of drugs that enter Phase III ultimately advance to regulatory review. See also: NDA, BLA, FDA.

Preclinical Research
Laboratory and animal studies conducted before a compound enters human clinical trials. Preclinical data demonstrates proof of concept, establishes safety parameters, and forms the scientific foundation of an IND application. Most compounds never make it out of preclinical development. See also: IND, Drug Discovery.

★ Precision Medicine
An approach to medicine that tailors treatment to the individual characteristics of each patient — including genetics, environment, and lifestyle. Precision medicine is enabled by genomics, biomarkers, and AI-driven data analysis. The global precision medicine market exceeded $90B in 2024 and is among the fastest-growing areas in life sciences. See also: Genomics, Biomarker.

PMA (Premarket Approval)
The most rigorous FDA regulatory pathway for high-risk medical devices. PMA requires valid scientific evidence — typically including clinical data — demonstrating safety and effectiveness. It’s used for devices such as implantable cardiac defibrillators, cochlear implants, and certain AI-powered diagnostic tools. See also: 510(k), De Novo.

★ Pre-Seed Funding
The earliest stage of startup financing, typically used to validate a concept, file initial IP, or conduct proof-of-concept research. Pre-seed capital often comes from founders’ own resources, friends and family, or angel investors. It’s the stage that most founders navigate alone before institutional investors get involved. See also: Angel Investor, Series A/B/C.

R

★ Rare Disease
A disease affecting fewer than 200,000 people in the US (or fewer than 1 in 2,000 in Europe). Despite their individual rarity, there are approximately 7,000 rare diseases affecting an estimated 300 million people globally. Only about 5% of rare diseases have an approved treatment, making this a high-priority and commercially attractive area for biotech. See also: Orphan Drug.

★ Regulatory Affairs
The discipline responsible for guiding products through the regulatory approval process. Regulatory affairs professionals develop submission strategies, manage agency interactions, and ensure ongoing compliance with applicable laws and guidelines. A well-staffed regulatory affairs team is among the most valuable assets a life sciences company can have.

Research Tools
Products and technologies — including reagents, assay kits, imaging systems, and software platforms — used in biological and medical research. Research tools are a key sub-sector of California’s life sciences industry, often generating recurring revenue that funds longer-duration therapeutic development programs.

Return on Investment (ROI)
A measure of the profitability of an investment relative to its cost. In life sciences, ROI timelines are extended by the drug development process — often 10–15 years from discovery to market. Understanding ROI expectations is critical for founders managing investor relationships and for investors structuring portfolio strategies.

Royalty
A payment made to an IP holder for ongoing use of their licensed property, typically calculated as a percentage of net product sales. Royalty rates in life sciences typically range from 1–15%, depending on the stage of development at which a deal is struck, the therapeutic area, and the commercial potential of the asset. See also: Licensing, Milestone Payment.

S

★ Series A / B / C Financing
Successive rounds of institutional venture capital funding, each representing a stage of company maturity. Series A typically funds early clinical development; Series B expands clinical programs; Series C supports late-stage trials or pre-commercialization activities. Each round carries higher expectations for clinical and operational milestones. See also: Venture Capital, Equity Financing.

★ Small Molecule Drug
A low-molecular-weight chemical compound that modulates a biological target. Small molecules are the traditional class of pharmaceuticals — including aspirin, statins, and kinase inhibitors — and are typically synthesized chemically, manufactured at scale, and delivered orally. See also: Biologic.

Startup
An early-stage company building a scalable product or service, typically with a focus on rapid growth and a path to an exit. Life sciences startups often originate in university labs or established company spin-outs and require substantial capital investment over many years before reaching profitability or commercial scale.

STEM
Science, Technology, Engineering, and Mathematics — the educational and professional fields that underpin the life sciences workforce. California’s STEM talent pipeline, anchored by the UC and CSU systems and elite private universities, is a core competitive advantage of the state’s ecosystem.

Synthetic Biology
The design and construction of new biological parts, devices, and systems not found in nature — or the systematic redesign of existing biological systems for useful purposes. Applications span drug manufacturing, agricultural biotech, industrial enzymes, biofuels, and sustainable materials.

T

★ Target
A biological molecule — typically a protein or gene — whose activity is associated with a disease and which a drug is designed to modulate. Target identification (finding which molecule to go after) and target validation (confirming that modulating it produces the desired effect) are the first and most consequential steps of the drug discovery process.

Technology Transfer
The process of transferring scientific discoveries from research institutions — such as universities and national labs — to the commercial sector for development into products. California’s university tech transfer offices at UCSF, Stanford, UCLA, and UC San Diego are among the most prolific in the world, generating dozens of new company formations each year.

Therapeutic Area
A disease or clinical domain in which a company focuses its research and development. Common therapeutic areas include oncology, neurology, cardiovascular disease, immunology, infectious disease, and rare diseases. Focus matters: deep therapeutic area expertise is a major competitive advantage in clinical development and regulatory strategy.

Toxicology
The study of adverse effects of chemical or biological agents on living organisms. Toxicology studies are a required component of preclinical development and inform safe dosing ranges for early clinical trials. Unexpected toxicology findings are among the most common reasons drug programs are discontinued before human testing.

Translational Research
Research that “translates” basic scientific discoveries into clinical applications — bridging the gap between the laboratory bench and the patient’s bedside. Translational research programs are a key strength of California’s academic medical centers, including UCSF, UCLA, and Cedars-Sinai, and are frequently the origin point for new company formation.

V

Valuation
An estimate of a company’s total worth, determined by investors during financing rounds. Life sciences valuations are heavily influenced by the stage and quality of clinical assets, IP position, team credentials, competitive landscape, and broader market conditions. Biotech valuations can shift dramatically based on clinical data readouts.

Vector (Viral Vector)
A vehicle used to deliver genetic material into cells. In gene therapy, viral vectors — particularly adeno-associated viruses (AAVs) and lentiviruses — are engineered to carry therapeutic genes to target tissues. Vector design, tropism, and manufacturing are critical technical challenges in the gene therapy field. See also: Gene Therapy.

★ Venture Capital (VC)
Institutional investment funds that provide financing to early- and growth-stage companies in exchange for equity. Venture capital is the primary funding mechanism for life sciences startups. California — particularly the Bay Area and San Diego — is home to many of the world’s leading life sciences VC firms. US life sciences VC investment totaled approximately $28B in 2024. See also: Series A/B/C, Angel Investor.

W

Women in Bio (WIB)
A specialized track within California Life Sciences’ FAST Program supporting women founders in life sciences. Women in Bio reflects CLS’s commitment to building a diverse and inclusive innovation ecosystem — and addresses a well-documented gap in life sciences funding, where women-led companies have historically received a disproportionately small share of venture capital.

Conclusion

California’s ecosystem gives founders, investors, and scientists an extraordinary environment in which to do this work. The density of talent, capital, and institutional knowledge here is unmatched globally — and it all runs on a shared vocabulary.

Bookmark this glossary and come back as you encounter new terms. We update it regularly as the industry and its language evolve.

This glossary is maintained by California Life Sciences. Definitions reflect common industry usage and are intended as a starting-point reference, not legal or regulatory guidance. Last updated: March 2026.